Investment
Features
FeesSafety
Academy
More
Pluang+

Senator urges probe into Tether's compliance after USDT linked to Iran sanctions violations.

Market News
06 Oct 2026
Tokenpost
View Source
Bearish
Senator urges probe into Tether's compliance after USDT linked to Iran sanctions violations.

Senator Richard Blumenthal has called on the U.S. Treasury and Justice Departments to investigate Tether's compliance with sanctions and anti-money laundering rules after a Senate analysis found heavy use of Tether's USDT stablecoin among wallets linked to Iran and its proxies. The analysis covered transactions from 2021 to 2026 and revealed that 84% of these wallets transacted predominantly in USDT, including sanctioned Iranian oil smugglers moving over $600 million. While Tether denies wrongdoing and highlights cooperation with law enforcement, the senator's inquiry seeks clarity on any ongoing investigations and compliance measures. This scrutiny could impact regulatory oversight of stablecoins and crypto firms tied to sanctioned entities.

The story on Senator Blumenthal's call for investigations into Tether comes as Pluang's market breadth shows 24 of 50 major cryptocurrencies rose while 25 fell. Notable movers include COTI with a price of Rp244 and a 1-day change of -3.31%, UNI at Rp154.755 down 3.26%, and SAND priced at Rp1.170 with a 3.16% decline. This snapshot is as of Oct 07, 2026 01:12 WIB.

More News

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK to report Q3 2026 earnings on Oct 20 amid Citigroup's Sell rating at $45.59

Bank OZK is scheduled to release its Q3 2026 earnings after market close on October 20, providing investors with updated financial results to compare against Citigroup's current Sell rating. The bank's latest balance sheet shows $41.70 billion in tot...

Company Fundamentals
Neutral
35 minutes ago
Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank raises Pfizer price target to $33, signaling 20.9% potential gain.

Scotiabank has increased its price target for Pfizer stock from $30.00 to $33.00, suggesting a potential upside of 20.9% from the current trading price of $27.31. Pfizer, a major pharmaceutical company, holds a strong buy rating with a Zacks Rank of ...

Analyst Insights
Bullish
1 hour ago
Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup raises AstraZeneca price target after strong clinical trial results

Citigroup has raised its price target for AstraZeneca to £186.00 from £178.00, maintaining a Buy rating following successful Phase 3 clinical trials. The increase reflects higher peak sales forecasts for drugs tozorakimab and SERENA-6, offsetting the...

Analyst Insights
Bullish
1 hour ago
Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

Devon Energy shares seen rising 40% as analyst sets $67 price target amid asset sale pressures.

An analyst from BMO Capital set a $67 price target for Devon Energy, suggesting a 40% upside from its current share price of around $48. The oil and gas producer has consistently beaten earnings estimates recently, showing strong financial health. Ho...

Analyst Insights
Bullish
2 hours ago
$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

$10,000 in Marvell stock 10 years ago is now worth about $206,000, needing 35% annual growth to repeat.

An investment of $10,000 in Marvell stock a decade ago has grown to approximately $206,000 today. Achieving the same growth again would require an annual earnings increase of 35%. This highlights Marvell's strong past performance and the challenge of...

Market News
Bullish
2 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App